A phase II study of an aptameric von Willebrand factor antagonist, ARC1779, in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Trial Profile

A phase II study of an aptameric von Willebrand factor antagonist, ARC1779, in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Egaptivon pegol (Primary) ; Abciximab
  • Indications Myocardial infarction; Thrombosis
  • Focus Biomarker; Therapeutic Use
  • Acronyms vITAL-1
  • Most Recent Events

    • 08 Jan 2009 Status changed from active, no longer recruiting to discontinued, according to clinicaltrials.gov.
    • 09 Nov 2007 Status changed from initiated to recruiting.
    • 01 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top